Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK4524101 |
Synonyms | |
Therapy Description |
GSK4524101 inhibits DNA polymerase theta, which may prevent the repair of DNA-double stranded breaks, resulting in decreased tumor cell proliferation (Cancer Res (2024) 84 (7_Supplement): CT169, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK4524101 | GSK 4524101|GSK-4524101 | GSK4524101 inhibits DNA polymerase theta, which may prevent the repair of DNA-double stranded breaks, resulting in decreased tumor cell proliferation (Cancer Res (2024) 84 (7_Supplement): CT169, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06077877 | Phase Ib/II | GSK4524101 + Niraparib GSK4524101 Niraparib | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Recruiting | USA | CAN | 0 |